Sclerosis News and Research

RSS

Discovery opens new possibility of designing drugs for amyotrophic lateral sclerosis

Researchers at Lund University, Sweden, have taken a snapshot of proteins changing shape, sticking together and creating structures that are believed to trigger deadly processes in the nervous system. The discovery opens the possibility of designing drugs for a devastating neurological disease, ALS.

13 Oct 2009

New mouse models resembles human ALS; may provide important tool for screening new drugs

A new mouse model of amyotrophic lateral sclerosis (ALS) closely resembles humans with the paralyzing disorder, researchers at Washington University School of Medicine in St. Louis report.

13 Oct 2009

Mouse model of ALS closely resembles humans with the paralyzing disorder, says report

A new mouse model of amyotrophic lateral sclerosis (ALS) closely resembles humans with the paralyzing disorder, researchers at Washington University School of Medicine in St. Louis report.

13 Oct 2009

Guidelines for treating amyotrophic lateral sclerosis identified

New guidelines from the American Academy of Neurology identify the most effective treatments for amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease. The guidelines are published in the October 13, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology.

13 Oct 2009

New guidelines for treating amyotropic lateral sclerosis

Dr. John England, Professor and Chairman of Neurology at LSU Health Sciences Center New Orleans, analyzed research findings and was responsible for the quality and accuracy of evidence analysis and the conclusions of the studies resulting in new guidelines for treating Lou Gehrig's disease, or amyotropic lateral sclerosis (ALS).

13 Oct 2009

Female lawmakers shape health care with their own stories

CQ Politics reports that Rep. Mary Jo Kilroy, D-Ohio, is one of several women lawmakers who is using her own history with multiple sclerosis to lobby for changes in the health care system: "As the health care debate rages on, [Kilroy] has decided to use her personal story to help fellow lawmakers understand how important it is to make health care available for all Americans. In a 'Dear Colleague' letter she sent last week, Kilroy told them about her own diagnosis."

12 Oct 2009

Wake Forest University School of Medicine honours researchers

Wake Forest University School of Medicine honored eight of its researchers with awards for excellence at the 13th Annual Research Awards Day Oct. 1.

12 Oct 2009

PPA bus tour to raise awareness of patient assistance programs

The 'Help is Here Express' bus tour will be stopping in Iowa, Southern Illinois, and Southern Indiana throughout the week of October 12 -- 16th at various cities in order to help uninsured and financially-struggling Midwesterners access information on programs that provide prescription medicines for free or nearly free.

12 Oct 2009

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo

9 Oct 2009

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009.

9 Oct 2009

Inclusion of vitamin D values in National Nutrient Database

The next time you run nutritionals using the government's database, you might be pleasantly surprised that some of your favorite foods seem to have received a nutrient boost, virtually overnight.

9 Oct 2009

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic cancer and rheumatoid arthritis.

9 Oct 2009

Premature aging of immune system develops amyotrophic lateral sclerosis

Premature aging of the immune system appears to play a role in the development of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to research scientists from the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai Medical Center, the Weizmann Institute of Science in Israel, and Sheba Medical Center in Israel.

9 Oct 2009

New cancer drugs boost drug spending

Cancer treatments are on track to become the biggest driver of specialty pharmacy spending as its contribution to overall drug spending hit five percent for the first time in the first half of 2009, according to Medco Health Solutions, Inc.

8 Oct 2009

New Leaf Brands' initiative to find cure for MS, will sponsor a participating team for bike ride event

New Leaf Brands, a wholly owned subsidiary of Baywood International, Inc. (OTCBB: BAYW) ("Company"), today announced that the Company will sponsor a participating team in the Multiple Sclerosis/Tappan Zee Bike Ride taking place on Sunday, October 18, 2009 in Tarrytown, New York.

8 Oct 2009

Nutra Pharma to launch prescription analgesic for severe chronic pain treatment

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain.

7 Oct 2009

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

AVANIR Pharmaceuticals, Inc. today announced it will present detailed data from the Phase III confirmatory STAR trial in the treatment of pseudobulbar affect (PBA) at the 3rd World Congress on Controversies in Neurology (CONy) in Prague, Czech Republic on October 8 - 11, 2009 and the American Neurological Association (ANA) 134th Annual Meeting in Baltimore, MD on October 11 - 14, 2009.

6 Oct 2009

Multiple Sclerosis Association of America receives National Health Information Awards

The Multiple Sclerosis Association of America (MSAA) received four communications awards, which included two APEX Awards and two National Health Information Awards.

5 Oct 2009

Myocardial and neurological effects of Tβ4 presented

REGENERX BIOPHARMACEUTICALS, INC. today reported on the results of several important research programs with Thymosin beta 4 (Tβ4) presented at the Second International Symposium on Thymosins in Health and Disease, in Catania, Italy.

5 Oct 2009

National experts to address epilepsy disorder

The Epilepsy Foundation of Minnesota is partnering with Mayo Clinic to host a regional patient education conference called “Living with Seizures: Today & Tomorrow.” The regional conference will feature national experts in epilepsy, panel discussions and breakout sessions that include the following topics:

5 Oct 2009

Sclerosis News and Research

Discovery opens new possibility of designing drugs for amyotrophic lateral sclerosis

New mouse models resembles human ALS; may provide important tool for screening new drugs

Mouse model of ALS closely resembles humans with the paralyzing disorder, says report

Guidelines for treating amyotrophic lateral sclerosis identified

New guidelines for treating amyotropic lateral sclerosis

Female lawmakers shape health care with their own stories

Wake Forest University School of Medicine honours researchers

PPA bus tour to raise awareness of patient assistance programs

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

Inclusion of vitamin D values in National Nutrient Database

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Premature aging of immune system develops amyotrophic lateral sclerosis

New cancer drugs boost drug spending

New Leaf Brands' initiative to find cure for MS, will sponsor a participating team for bike ride event

Nutra Pharma to launch prescription analgesic for severe chronic pain treatment

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

Multiple Sclerosis Association of America receives National Health Information Awards

Myocardial and neurological effects of Tβ4 presented

National experts to address epilepsy disorder

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News